Expiration Date: 10/09/2024
*Please note that you must complete the Post Webinar Evaluation (link below) to receive CE credit.
Franklin King IV, MD
Director of Training & Education
Massachusetts General Hospital
James Whitledge, MD
Herbs and Dietary Supplements Section Co-Chair
University of Vermont Medical Center
David Vearrier, MD, MPH
Professor of Emergency Medicine
University of Mississippi Medical Center
Toxicologists typically view psychedelics, including those that are plant-derived, from a pathologic perspective, as we frequently treat patients with toxicity after psychedelic exposure. However, psychedelic substances also represent a promising therapeutic frontier for the treatment of psychiatric disease, and in coming years psychedelic-based therapeutics may become more widely available. Toxicologists must be aware of the medicinal applications of psychedelics in addition to harms as the trend towards clinical applications of psychedelics continues. Dr. King will provide a 60-minute lecture on the therapeutic applications and benefits of psychedelics, in particular those that are plant-derived.
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Academy of Clinical Toxicology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM for physicians and 1 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
Objectives - After attending this program you should be able to:
- Describe the current state of psychedelic research.
- Identify the current therapeutic applications of psychedelics.
- Discuss expected future trends in psychedelics research and clinical applications.
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.